Compare Citius Pharmaceuticals Inc (CTXR) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs SiTime Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while SiTime Corporation trades at $684.4 (market cap $20.73B). The key difference: SiTime Corporation is far larger — about 1106.8× Citius Pharmaceuticals Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | SITM | |
|---|---|---|
Market Cap | $18.73M | $20.73B |
Sector | Health | Technology |
52-Week High | $1.82 | $901.60 |
52-Week Low | $0.48 | $212.77 |
Enterprise Value | $14.95M | $20.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
SITM stock surged 5.5% to $725.28, showing strong momentum with three consecutive quarterly earnings beats and bullish technical indicators. The company reported 127% revenue growth in Q2 2026 and expects further acceleration from AI infrastructure demand and the Renesas acquisition. Despite negative 2025 earnings, profitability improved significantly with net income turning positive in 2026 projections.
Outlook remains positive with 100% analyst buy ratings and $870 consensus target, though premium valuations (P/E 1,148, P/S 39) and execution risks from the Renesas integration warrant caution. AI timing growth presents substantial opportunity, but stock appears fully valued after recent run-up.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
